A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2019
At a glance
- Drugs Ganaxolone (Primary)
- Indications Epilepsy
- Focus Proof of concept; Therapeutic Use
- Sponsors Marinus Pharmaceuticals
- 01 Jul 2019 Status changed to active, no longer recruiting.
- 01 Jul 2019 Planned End Date changed from 1 Jan 2019 to 1 Jun 2021.
- 27 Mar 2019 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History